156 related articles for article (PubMed ID: 35899977)
1. A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.
Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Kleiman R; Agbo F; Olanow CW; Blum D; Navia B
Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1068-1077. PubMed ID: 35899977
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
6. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
7. Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants.
Lissy M; Demmel V; Sachse R; Ammer N; Kelepouris N; Ostrow V
Clin Pharmacol Drug Dev; 2021 May; 10(5):494-501. PubMed ID: 32961034
[TBL] [Abstract][Full Text] [Related]
8. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
[TBL] [Abstract][Full Text] [Related]
9. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1-phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study.
Darpo B; Connor K; Cabell CH; Grundy JS
Clin Pharmacol Drug Dev; 2024 Apr; 13(4):326-340. PubMed ID: 38441346
[TBL] [Abstract][Full Text] [Related]
13. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
[TBL] [Abstract][Full Text] [Related]
14. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
Stier B; Fossler M; Liu F; Caltabiano S
Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
[TBL] [Abstract][Full Text] [Related]
15. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
16. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
17. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.
Parkinson J; Dota C; Källgren C; Gottfridsson C; Bjursell M; Perl S; Kӧrnicke T; Rekić D; Johansson S
Br J Clin Pharmacol; 2023 Jun; 89(6):1747-1755. PubMed ID: 36504291
[TBL] [Abstract][Full Text] [Related]
18. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
Mueller MS; Sidharta PN; Voors-Pette C; Darpo B; Xue H; Dingemanse J
Orphanet J Rare Dis; 2020 Oct; 15(1):303. PubMed ID: 33109218
[TBL] [Abstract][Full Text] [Related]
19. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S;
Ther Adv Neurol Disord; 2023; 16():17562864231209240. PubMed ID: 37954918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]